| Chronic graft-versus-host disease

Niktimvo vs Jakafi

Side-by-side clinical, coverage, and cost comparison for chronic graft-versus-host disease.

Deep comparison between: Niktimvo vs Jakafi with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsJakafi has a higher rate of injection site reactions vs Niktimvo based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Jakafi but not Niktimvo, including UnitedHealthcare

Category

Niktimvo

Jakafi

At A Glance

RouteIV infusion

FrequencyEvery 2 weeks

ClassCSF-1R antagonist

RouteOral

FrequencyTwice daily

ClassJAK1/JAK2 inhibitor

Indications

Chronic graft-versus-host disease

Myelofibrosis
Polycythemia Vera
Acute GVH disease
Chronic graft-versus-host disease

Dosing

Chronic graft-versus-host disease 0.3 mg/kg (maximum 35 mg) as an intravenous infusion over 30 minutes every 2 weeks until progression or unacceptable toxicity; for patients weighing at least 40 kg.

Myelofibrosis Starting dose based on platelet count: 20 mg orally twice daily (>200 x 10^9/L), 15 mg twice daily (100-200 x 10^9/L), or 5 mg twice daily (50 to <100 x 10^9/L); doses may be titrated up to 25 mg twice daily based on safety and efficacy.

Polycythemia Vera 10 mg orally twice daily starting dose; doses may be titrated up to 25 mg twice daily based on safety and efficacy.

Acute GVH disease 5 mg orally twice daily starting dose; may increase to 10 mg twice daily after at least 3 days if ANC and platelet counts are not decreased by 50% or more relative to the first day of dosing.

Chronic graft-versus-host disease 10 mg orally twice daily starting dose; taper after 6 months in patients with response who have discontinued therapeutic doses of corticosteroids.

Contraindications

—

Drug Interactions

163View drug interactions

1324View drug interactions

Adverse Reactions

Most common (>=15%) Increased AST, infection (pathogen unspecified), increased ALT, decreased phosphate, decreased hemoglobin, viral infection, increased GGT, musculoskeletal pain, increased lipase, fatigue, increased amylase, increased calcium, increased CPK, increased ALP, nausea, headache, diarrhea, cough, bacterial infection, pyrexia, dyspnea

Serious Infection (pathogen unspecified), viral infection, respiratory failure

Most common Thrombocytopenia, anemia, neutropenia, bruising, dizziness, headache, infections, edema, hemorrhage, fatigue

Serious Thrombocytopenia, anemia, neutropenia, infections, non-melanoma skin cancer, major adverse cardiovascular events, thrombosis, secondary malignancies

Postmarketing Herpes simplex virus reactivation and/or dissemination

Pharmacology

Axatilimab-csfr is a CSF-1R antagonist; a monoclonal antibody that binds to colony stimulating factor-1 receptors (CSF-1R) on monocytes and macrophages, reducing circulating proinflammatory and profibrotic monocytes and monocyte-derived macrophages, and inhibiting the activity of pathogenic macrophages in tissues.

Ruxolitinib is a kinase inhibitor that selectively inhibits JAK1 and JAK2, which mediate cytokine and growth factor signaling important for hematopoiesis and immune function; dysregulated JAK1/JAK2 signaling underlies myelofibrosis, polycythemia vera, and GVHD pathogenesis.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Niktimvo